A new safety update to the US prescribing information for Biogen, Inc.'s Aduhelm (aducanumab) – the first-of-its-kind, anti-amyloid antibody for Alzheimer's disease – presents more obstacles to use, but the drug already has been mostly sidelined by access restrictions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?